share_log

Is Now An Opportune Moment To Examine Quest Diagnostics Incorporated (NYSE:DGX)?

Is Now An Opportune Moment To Examine Quest Diagnostics Incorporated (NYSE:DGX)?

現在是審查奎斯特診療有限公司(紐交所:DGX)的適當時機嗎?
Simply Wall St ·  11/11 07:28

Today we're going to take a look at the well-established Quest Diagnostics Incorporated (NYSE:DGX). The company's stock saw its share price hover around a small range of US$146 to US$159 over the last few weeks. But is this actually reflective of the share value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Quest Diagnostics's outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

今天我們將深入了解成熟的奎斯特診療公司(紐交所: DGX)。公司股票價格在過去幾周內徘徊在146美元至159美元的小區間內。但這是否真正反映了這家大市值公司的股票價值呢?還是目前被低估了,爲我們提供了買入的機會?讓我們基於最新財務數據來看一看奎斯特診療的展望和價值,看看是否存在任何導致股價變動的催化劑。

What Is Quest Diagnostics Worth?

奎斯特診療的價值是多少?

According to our price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 21.23x is currently trading slightly below its industry peers' ratio of 25.4x, which means if you buy Quest Diagnostics today, you'd be paying a decent price for it. And if you believe Quest Diagnostics should be trading in this range, then there isn't much room for the share price to grow beyond the levels of other industry peers over the long-term. Furthermore, Quest Diagnostics's share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. This may mean it is less likely for the stock to fall lower from natural market volatility, which suggests less opportunities to buy moving forward.

根據我們的價格倍數模型,該模型對比了公司的市盈率和行業平均值,股價似乎是合理的。我們在這種情況下使用市盈率,因爲沒有足夠的可見性來預測其現金流。該股的21.23倍市盈率目前略低於行業同行的25.4倍,這意味着如果今天購買奎斯特診療,您將爲此支付一個合理的價格。如果您相信奎斯特診療應該在這個區間內交易,那麼長期來看,股價增長的空間將不高於其他行業同行的水平。此外,與市場其他部分相比,奎斯特診療的股價也相對穩定,這可以從其低貝塔值表明。這可能意味着其股票不太可能因自然市場波動而進一步下跌,這表明未來買入機會較少。

What does the future of Quest Diagnostics look like?

奎斯特診療的未來展望如何?

big
NYSE:DGX Earnings and Revenue Growth November 11th 2024
紐交所: DGX盈利和營業收入增長2024年11月11日

Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Quest Diagnostics' earnings over the next few years are expected to increase by 56%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

未來展望是您考慮購買股票時的一個重要方面,尤其是如果您是一位尋求投資組合增長的投資者。儘管價值投資者會認爲相對價格的內在價值是最重要的,但一個更具吸引力的投資論點將是以低價獲得高增長潛力。奎斯特診療在未來幾年的收益預計將增長56%,預示着前景樂觀。這將導致更加穩健的現金流,反哺更高的股票價值。

What This Means For You

這對你意味着什麼

Are you a shareholder? DGX's optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at DGX? Will you have enough conviction to buy should the price fluctuate below the industry PE ratio?

您是股東嗎?DGX樂觀的未來增長已經反映在當前股價中,股票交易價格接近行業價格的倍數。然而,還有其他重要因素我們今天沒有考慮到,比如公司的財務實力。自您上次查看DGX以來,這些因素有變化嗎?如果價格波動低於行業市盈率,您能否擁有足夠的信心買入?

Are you a potential investor? If you've been keeping an eye on DGX, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the positive outlook is encouraging for DGX, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

您是潛在投資者嗎?如果您一直關注DGX,現在可能不是最有利的買入時機,因爲它的交易價格接近行業價格的倍數。然而,DGX的積極前景令人鼓舞,這意味着值得深入研究其他因素,比如其資產負債表的實力,以便利用下一次價格下跌。

So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. You'd be interested to know, that we found 1 warning sign for Quest Diagnostics and you'll want to know about it.

因此,如果您想深入了解這支股票,重要的是考慮它所面臨的任何風險。您可能會感興趣知道,我們發現了奎斯特診療的1個警告信號,您會想知道這些內容。

If you are no longer interested in Quest Diagnostics, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

如果您對奎斯特診療不再感興趣,您可以使用我們的免費平台查看我們超過50支其他潛在高增長的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論